IRF3 Promotes Asthma Pathogenesis by Regulating Type 2 Innate Lymphoid Cells.

Area of Science:

• Immunology
• Respiratory Medicine
• Molecular Biology

Background:

• Allergic asthma involves airway hyperresponsiveness driven by inhaled allergens.
• Type 2 innate lymphoid cells (ILC2s) secrete cytokines that promote airway inflammation.
• Mechanisms governing lung ILC2 function in asthma are not fully understood.

Purpose of the Study:

• Investigate the role of Interferon regulatory factor 3 (IRF3) in ILC2s from asthma patients and mouse models.
• Determine the impact of IRF3 deficiency on ILC2 function in an IL33-induced asthma model.
• Elucidate the mechanisms of IRF3-mediated regulation of ILC2s, including Gata3 involvement.

Main Methods:

• Examined IRF3 expression in ILC2s from human asthma patients and mouse models.
• Utilized IRF3-deficient mice to study IL33-induced asthma.
• Assessed ILC2 expansion, function, and Gata3 regulation in the context of IRF3 deficiency.

Main Results:

• IRF3 expression is elevated in ILC2s of asthma patients and mice.
• IRF3 deficiency impairs ILC2 expansion and function in an IL33-induced asthma model.
• IRF3 regulation of ILC2s is independent of Th2 cells and mediated by Gata3.

Conclusions:

• IRF3 is identified as a novel regulator of lung ILC2s.
• IRF3 plays a critical role in ILC2-mediated responses in allergic asthma.
• IRF3 presents a potential immunotherapeutic target for allergic asthma treatment.